Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
211915-06-9
Molecular formula
C34H41N7O5
Molecular weight
627.73 g/mol
Drug class
Oral direct thrombin inhibitor prodruganticoagulant
Mechanism of action
Dabigatran etexilate is an orally administered prodrug converted by esterases to dabigatran, a direct, competitive inhibitor of free and clot-bound thrombin. Thrombin inhibition prevents fibrin formation and thrombin-mediated platelet activation.
Indications / reported uses
Prevention of stroke and systemic embolism in eligible adults with non-valvular atrial fibrillation
Treatment of deep-vein thrombosis (DVT) and pulmonary embolism (PE) after initial parenteral anticoagulation, and reduction of recurrent DVT/PE risk
Primary prevention of venous thromboembolic events after hip replacement surgery in adults; paediatric indications and dosing are product-label specific
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Dabigatran Etexilate Environmental Risk Assessment (ERA) (the Dabigatran Etexilate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.